HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released. This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been particularly hard hit, as eight of the top twelve public donors cut their funding in 2010. Now is a time of tremendous opportunity, with dozens of potential products within the reach of patients–donors must commit to taking them across the finish line.
The Stop TB Partnership has provided information and references to help partners to prepare a successful proposal to The Global Fund to Fight HIV/AIDS, Tuberculosis, and Malaria. The call for Round 11 applications was released on August 15. Go to http://www.stoptb.org/global/tbfriends/ to get more information.
The fund that fights killer diseases such as TB and Aids needs to build on its success, but it is facing a fiscal crisis. World leaders will come together at the United Nations in September in order to accelerate progress towards the Millennium Development Goals (MDGs). Three of the eight MDGs involve bringing primary health services to the entire world’s population. A small amount of global funding, if well directed, could save millions of lives each year. The key step is to expand the Global Fund to Fight Aids, Tuberculosis, and Malaria into a Global Health Fund.